1508-65-2 | Oxybutynin hydrochloride

Packsize	Purity	Availability	Price	Discounted Price
250mg	98%	in stock	$28.00	$20.00
1g	98%	in stock	$58.00	$41.00
5g	98%	in stock	$201.00	$141.00
25g	98%	in stock	$660.00	$462.00

Description

• Catalog Number: AD46475
• Chemical Name: Oxybutynin hydrochloride
• CAS Number: 1508-65-2
• Molecular Formula: C22H32ClNO3
• Molecular Weight: 393.9474
• MDL Number: MFCD19300763
• SMILES: CCN(CC#CCOC(=O)C(c1ccccc1)(C1CCCCC1)O)CC.Cl
• NSC Number: 759108

Computed Properties

• Complexity: 490
• Covalently-Bonded Unit Count: 2
• Heavy Atom Count: 27
• Hydrogen Bond Acceptor Count: 4
• Hydrogen Bond Donor Count: 2
• Rotatable Bond Count: 8
• Undefined Atom Stereocenter Count: 1

Literature

• Pharmacokinetics and toxicity of antimuscarinic drugs for overactive bladder treatment in females.

  Expert opinion on drug metabolism & toxicology 20121101

• Desmopressin and oxybutynin in monosymptomatic nocturnal enuresis: a randomized, double-blind, placebo-controlled trial and an assessment of predictive factors.

  BJU international 20121001

• Cognitive effects of oxybutynin chloride topical gel in older healthy subjects: a 1-week, randomized, double-blind, placebo- and active-controlled study.

  Clinical drug investigation 20121001

• Early administration of oxybutynin improves bladder function and clinical outcomes in newborns with posterior urethral valves.

  The Journal of urology 20121001

• Intravesical treatment of painful bladder syndrome: a systematic review and meta-analysis.

  International urogynecology journal 20120901

• An evaluation of patient and physician satisfaction with controlled-release oxybutynin 15 mg as a one-step daily dose in elderly and non-elderly patients with overactive bladder: results of the STOP study.

  Current medical research and opinion 20120801

• Bryophyllum pinnatum inhibits detrusor contractility in porcine bladder strips--a pharmacological study towards a new treatment option of overactive bladder.

  Phytomedicine : international journal of phytotherapy and phytopharmacology 20120715

• Cost-effectiveness analysis of newer anticholinergic drugs for urinary incontinence vs oxybutynin and no treatment using data on persistence from the Swedish prescribed drug registry.

  BJU international 20120701

• The effects of oxybutynin on urinary symptoms in children with Williams-Beuren syndrome.

  The Journal of urology 20120701

• [Hyperthermia in spina bifida patients treated with oxybutynin].

  Der Urologe. Ausg. A 20120701

• Patient-reported goal achievement after antimuscarinic treatment in patients with overactive bladder symptoms.

  International journal of clinical practice 20120701

• Benefits and harms of pharmacologic treatment for urinary incontinence in women: a systematic review.

  Annals of internal medicine 20120619

• A randomized placebo-controlled trial of oxybutynin for the initial treatment of palmar and axillary hyperhidrosis.

  Journal of vascular surgery 20120601

• Oxybutynin gel for the treatment of overactive bladder.

  Expert opinion on pharmacotherapy 20120601

• Lower urinary tract symptoms revisited.

  International journal of clinical practice 20120601

• Conclusive identification of the oxybutynin-hydrolyzing enzyme in human liver.

  Drug metabolism and disposition: the biological fate of chemicals 20120501

• Effective and clinically meaningful non-hormonal hot flash therapies.

  Maturitas 20120501

• Efficacy and safety of oxybutynin chloride topical gel for women with overactive bladder syndrome.

  American journal of obstetrics and gynecology 20120201

• Prescription pattern of oxybutynin ER in patients with overactive bladder in real life practice: a multicentre, open-label, prospective observational study.

  International journal of clinical practice 20120201

• Which anticholinergic drug for overactive bladder symptoms in adults.

  The Cochrane database of systematic reviews 20120118

• Comparative adherence to oxybutynin or tolterodine among older patients.

  European journal of clinical pharmacology 20120101

• Got to go! Resolving day and night time enuresis in younger children.

  The journal of family health care 20120101

• [Catheter-related bladder discomfort in post-anaesthesia care unit].

  Annales francaises d'anesthesie et de reanimation 20120101

• An overview on mixed action drugs for the treatment of overactive bladder and detrusor overactivity.

  Urologia internationalis 20120101

• Combination of baclofen and antimuscarinics to reduce voiding difficulty in treating women with overactive bladders.

  Clinical and experimental obstetrics & gynecology 20120101

• An alternative to treat palmar hyperhidrosis: use of oxybutynin.

  Clinical autonomic research : official journal of the Clinical Autonomic Research Society 20111201

• Urothelial/lamina propria spontaneous activity and the role of M3 muscarinic receptors in mediating rate responses to stretch and carbachol.

  Urology 20111201

• Behavioral versus drug treatment for overactive bladder in men: the Male Overactive Bladder Treatment in Veterans (MOTIVE) Trial.

  Journal of the American Geriatrics Society 20111201

• Efficacy of oral extended-release oxybutynin in cognitively impaired older nursing home residents with urge urinary incontinence: a randomized placebo-controlled trial.

  Journal of the American Medical Directors Association 20111101

• The use of oxybutynin for treating axillary hyperhidrosis.

  Annals of vascular surgery 20111101

• Risk of serious falls associated with oxybutynin and tolterodine: a population based study.

  The Journal of urology 20111001

• [Retrospective studies and therapeutic research].

  Annales de dermatologie et de venereologie 20111001

• [Therapeutic value of moderate-dose oxybutynin in extensive hyperhidrosis].

  Annales de dermatologie et de venereologie 20111001

• Chronic use of oxybutynin and spinal anesthesia: a case of postoperative urinary retention and hematuria.

  Middle East journal of anaesthesiology 20111001

• Randomized trial of estradiol vaginal ring versus oral oxybutynin for the treatment of overactive bladder.

  Menopause (New York, N.Y.) 20110901

• Effect of oxybutynin and imidafenacin on central muscarinic receptor occupancy and cognitive function: a monkey PET study with [(11)C](+)3-MPB.

  NeuroImage 20110901

• Immediate-release oxybutynin for the treatment of clozapine-induced sialorrhea.

  The Annals of pharmacotherapy 20110901

• More treatment options for overactive bladder in postmenopausal women.

  Menopause (New York, N.Y.) 20110901

• A comprehensive non-clinical evaluation of the CNS penetration potential of antimuscarinic agents for the treatment of overactive bladder.

  British journal of clinical pharmacology 20110801

• Voiding dysfunction: another etiology of vulvovaginitis in young girls.

  Journal of pediatric and adolescent gynecology 20110801

• Validity and reliability of patient selected goals as an outcome measure in overactive bladder.

  International urogynecology journal 20110701

• Comparative analysis of the effects of antimuscarinic agents on bladder functions in both nonhuman primates and rodents.

  The Journal of pharmacology and experimental therapeutics 20110701

• Urinary incontinence, hyperthermia, and sudden death.

  Journal of forensic sciences 20110701

• Validity and reliability of the patient's perception of intensity of urgency scale in overactive bladder.

  BJU international 20110501

• Oxybutynin for treatment of nocturnal enuresis in children.

  Canadian family physician Medecin de famille canadien 20110501

• Determination of oxybutynin in pharmaceuticals via reaction with mixed acids anhydrides: application to content uniformity testing.

  Journal of fluorescence 20110301

• Anticholinergics do not improve cure rate of alarm treatment of monosymptomatic nocturnal enuresis.

  Urology 20110301

• Hollow fiber-based liquid-phase microextraction (HF-LPME) of isradipine and its main metabolite followed by chiral HPLC analysis: application to an in vitro biotransformation study.

  Analytical and bioanalytical chemistry 20110301

• Oxybutynin for antidepressant-induced hyperhidrosis.

  The American journal of psychiatry 20110301

• Editorial comment. Anticholinergics do not improve cure rate of alarm treatment of monosymptomatic nocturnal enuresis.

  Urology 20110301

• Evaluation of brain anticholinergic activities of urinary spasmolytic drugs using a high-throughput radio receptor bioassay.

  Journal of the American Geriatrics Society 20110301

• Selective binding of bladder muscarinic receptors in relation to the pharmacokinetics of a novel antimuscarinic agent, imidafenacin, to treat overactive bladder.

  The Journal of pharmacology and experimental therapeutics 20110201

• Oxybutynin and trospium are substrates of the human organic cation transporters.

  Naunyn-Schmiedeberg's archives of pharmacology 20110201

• Patient-selected goals in overactive bladder: a placebo controlled randomized double-blind trial of transdermal oxybutynin for the treatment of urgency and urge incontinence.

  BJU international 20110101

• [Comparisons of efficacy and safety of tolterodine and oxybutynin in children with idiopathic overactive bladder].

  Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics 20110101

• Urodynamic parameters development and complications of clean intermittent self-catheterization in Chinese schoolchildren with neurogenic underactive bladder.

  Urologia internationalis 20110101

• Pharmacokinetics of oxybutynin chloride topical gel: effects of application site, baths, sunscreen and person-to-person transference.

  Clinical drug investigation 20110101

• The use of oxybutynin for treating facial hyperhidrosis.

  Anais brasileiros de dermatologia 20110101

• Oxybutynin dependence: a case presentation.

  Turk psikiyatri dergisi = Turkish journal of psychiatry 20110101

• Cutaneous reactions to transdermal therapeutic systems.

  Dermatitis : contact, atopic, occupational, drug 20110101

• Idiopathic urgency urinary incontinence.

  The New England journal of medicine 20101230

• Intravesical oxybutynin protects the vesical wall against functional and smooth muscle changes in rabbits with detrusor overactivity.

  International urogynecology journal 20101201

• A predictive ligand-based Bayesian model for human drug-induced liver injury.

  Drug metabolism and disposition: the biological fate of chemicals 20101201

• Catalytic asymmetric dihydroxylation of enamides and application to the total synthesis of (+)-tanikolide.

  Angewandte Chemie (International ed. in English) 20101108

• Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.

  Bioorganic & medicinal chemistry letters 20101101

• Loss of muscarinic and purinergic receptors in urinary bladder of rats with hydrochloric acid-induced cystitis.

  Urology 20101001

• Sample size/power calculations for population pharmacodynamic experiments involving repeated-count measurements.

  Journal of biopharmaceutical statistics 20100901

• Correlation between pharmacologically-induced changes in cystometric parameters and spinal c-Fos expression in rats.

  Autonomic neuroscience : basic & clinical 20100825

• Efficacy, tolerability and safety of propiverine hydrochloride in comparison to oxybutynin in children with urge incontinence due to overactive bladder: Results of a multicentre observational cohort study.

  BJU international 20100801

• The cost-effectiveness of solifenacin vs fesoterodine, oxybutynin immediate-release, propiverine, tolterodine extended-release and tolterodine immediate-release in the treatment of patients with overactive bladder in the UK National Health Service.

  BJU international 20100801

• Oxybutynin and propiverine suppress adenosine triphosphate-induced bladder overactivity other than through antimuscarinic mechanisms.

  Urology 20100801

• Combined behavioral and individualized drug therapy versus individualized drug therapy alone for urge urinary incontinence in women.

  The Journal of urology 20100801

• Noninvasive evaluation of brain muscarinic receptor occupancy of oxybutynin, darifenacin and imidafenacin in rats by positron emission tomography.

  Life sciences 20100731

• Two unusual pediatric cases of dilutional hyponatremia.

  Pediatric emergency care 20100701

• New strategies for medical management of overactive bladder in children.

  Current opinion in urology 20100701

• Oxybutynin topical and transdermal formulations: an update.

  Drugs of today (Barcelona, Spain : 1998) 20100601

• Tolerability of 5 mg solifenacin once daily versus 5 mg oxybutynin immediate release 3 times daily: results of the VECTOR trial.

  The Journal of urology 20100501

• Treatment of generalized hyperhidrosis with oxybutynin in post-menopausal patients.

  Acta dermato-venereologica 20100501

• In women with urinary incontinence how necessary is cystometry?

  JPMA. The Journal of the Pakistan Medical Association 20100501

• Quantitative determination of oxybutynin hydrochloride by spectrophotometry, chemometry and HPTLC in presence of its degradation product and additives in different pharmaceutical dosage forms.

  Talanta 20100315

• The effect of intravesical oxybutynin on the ice water test and on electrical perception thresholds in patients with neurogenic detrusor overactivity.

  Neurourology and urodynamics 20100301

• Topical oxybutynin (Gelnique) for overactive bladder.

  The Medical letter on drugs and therapeutics 20100208

• Triple therapy in refractory detrusor overactivity: a preliminary study.

  World journal of urology 20100201

• Pediatrics: combining antimuscarinics shows promise for overactive bladder.

  Nature reviews. Urology 20100201

• Medication nonadherence secondary to drug-induced memory loss.

  The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists 20100201

• Oxybutynin permeation in skin: the influence of drug and solvent activity.

  International journal of pharmaceutics 20100115

• Editorial comment on: Cizolirtine citrate is safe and effective to treat urinary incontinence secondary to overactive bladder: a phase 2 proof-of-concept study.

  European urology 20100101

• Cizolirtine citrate is safe and effective for treating urinary incontinence secondary to overactive bladder: a phase 2 proof-of-concept study.

  European urology 20100101

• Editorial comment on: Cizolirtine citrate is safe and effective for treating urinary incontinence secondary to overactive bladder: a phase 2 proof-of-concept study.

  European urology 20100101

• Efficacy of combined oral-intravesical oxybutynin hydrochloride treatment for patients with overactive detrusors and indwelling urethral catheters.

  Rehabilitation nursing : the official journal of the Association of Rehabilitation Nurses 20100101

• Application of oxybutynin selective sensors for monitoring the dissolution profile and assay of pharmaceutical dosage forms.

  Analytical sciences : the international journal of the Japan Society for Analytical Chemistry 20100101

• A case of oxybutynin dependency.

  General hospital psychiatry 20100101

• Canadian cost-effectiveness analysis of solifenacin compared to oxybutynin immediate-release in patients with overactive bladder.

  Journal of medical economics 20100101

• Dose escalation improves therapeutic outcome: post hoc analysis of data from a 12-week, multicentre, double-blind, parallel-group trial of trospium chloride in patients with urinary urge incontinence.

  BMC urology 20100101

• Do anticholinergics affect reaction time? A possible impact on the course of rehabilitation.

  NeuroRehabilitation 20100101

• [Optimization of enuresis therapy in children using transcranial magnetotherapy].

  Urologiia (Moscow, Russia : 1999) 20100101

• Gelnique (oxybutynin chloride) 10% gel for overactive bladder.

  Urologic nursing 20100101

• [Intravesical electrostimulation and magnetophoresis in overactive bladder in females: efficacy of Amus-01-Intramag device with Intrastim attachment].

  Urologiia (Moscow, Russia : 1999) 20100101

• Cyclodextrin-MEEKC for the analysis of oxybutynin and its impurities.

  Talanta 20091215

• Intravesical oxybutynin in the pediatric neurogenic bladder.

  Nature reviews. Urology 20091201

• Oxybutynin chloride topical gel: a new formulation of an established antimuscarinic therapy for overactive bladder.

  Expert opinion on pharmacotherapy 20091201

• Primary hyperhidrosis controlled with oxybutynin after unsuccessful surgical treatment.

  Clinical and experimental dermatology 20091201

• Exploratory pilot study assessing the risk of cognitive impairment or sedation in the elderly following single doses of solifenacin 10 mg.

  Expert opinion on drug safety 20091101

• Trospium chloride and oxybutynin hydrochloride in a german study of adults with urinary urge incontinence: results of a 12-week, multicenter, randomized, double-blind, parallel-group, flexible-dose noninferiority trial.

  Clinical therapeutics 20091101

• Listening to the patient: a flexible approach to the use of antimuscarinic agents in overactive bladder syndrome.

  BJU international 20091001

• Comparison between oxybutynin, functional electrical stimulation and pelvic floor training for treatment of detrusor overactivity in women: a review.

  Current opinion in obstetrics & gynecology 20091001

• Efficacy and safety of oxybutynin transdermal system in spinal cord injury patients with neurogenic detrusor overactivity and incontinence: an open-label, dose-titration study.

  Urology 20091001

• Efficacy and safety of transdermal and oral oxybutynin in children with neurogenic detrusor overactivity.

  The Journal of urology 20091001

• Editorial comment.

  The Journal of urology 20091001

• Editorial comment.

  The Journal of urology 20091001

• Editorial comment.

  The Journal of urology 20091001

• Double anticholinergic therapy for refractory overactive bladder.

  The Journal of urology 20091001

• Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.

  Nature chemical biology 20091001

• [Effect of sublingual oxybutynin in postoperative pain after radical retropubic prostatectomy].

  Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie 20090901

• The evolution of transdermal therapy for overactive bladder.

  Current urology reports 20090901

• Spectrum of central anticholinergic adverse effects associated with oxybutynin: comparison of pediatric and adult cases.

  The Journal of pediatrics 20090901

• Comparison of muscarinic receptor selectivity of solifenacin and oxybutynin in the bladder and submandibular gland of muscarinic receptor knockout mice.

  European journal of pharmacology 20090801

• The effect of drug concentration on solvent activity in silicone membranes.

  International journal of pharmaceutics 20090730

• Urgency-free time interval as primary endpoint for evaluating the outcome of a randomized OAB treatment.

  International urogynecology journal and pelvic floor dysfunction 20090701

• Urinary incontinence: oxybutynin topical gel for overactive bladder.

  Nature reviews. Urology 20090701

• Estimating skin permeability from physicochemical characteristics of drugs: a comparison between conventional models and an in vivo-based approach.

  International journal of pharmaceutics 20090622

• Efficacy and safety of oxybutynin chloride topical gel for overactive bladder: a randomized, double-blind, placebo controlled, multicenter study.

  The Journal of urology 20090401

• Propiverine vs oxybutynin for treating neurogenic detrusor overactivity in children and adolescents: results of a multicentre observational cohort study.

  BJU international 20090301

• Restoring continence in frail older people living in the community: what factors influence successful treatment outcomes?

  Age and ageing 20090301

• Severe anticholinergic drug-induced delirium in a young adult after renal transplantation.

  Transplant international : official journal of the European Society for Organ Transplantation 20090201

• Protective action of intravesical oxybutynin on bladder ultrastructure in rabbits with detrusor overactivity.

  International urogynecology journal and pelvic floor dysfunction 20090201

• [Multinational clinical trial in Japan and Korea on detrusitol].

  Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan 20090201

• Effect of long-term oxybutynin administration on c-Fos expression in spinal neurons: inhibition of antimuscarinics on bladder afferents in conscious rats.

  Urology 20090101

• Transdermal oxybutynin.

  Drugs 20090101

• Solifenacin for overactive bladder in women unsuccessfully treated with immediate release oxybutynin: a pilot study.

  Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology 20090101

• Ratiometric Ca+2 measurement in human recombinant muscarinic receptor subtypes using the Flexstation scanning fluorometer.

  Journal of receptor and signal transduction research 20090101

• Impact of transdermal oxybutynin on work productivity in patients with overactive bladder: results from the MATRIX study.

  PharmacoEconomics 20090101

• Fatalities associated with clozapine-related constipation and bowel obstruction: a literature review and two case reports.

  Psychosomatics 20090101

• Enantioselective analysis of oxybutynin and N-desethyloxybutynin with application to an in vitro biotransformation study.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20081101

• Anticholinergic drugs, bladder retraining and their combination for urge urinary incontinence: a pilot randomised trial.

  International urogynecology journal and pelvic floor dysfunction 20081101

• The effects of reformulation: improved therapeutic index.

  Current urology reports 20081101

• A systematic review and meta-analysis of randomized controlled trials with antimuscarinic drugs for overactive bladder.

  European urology 20081001

• Sonographic evaluation of gallbladder contractility in patients with spinal cord injury.

  Journal of clinical ultrasound : JCU 20081001

• The relevance of urodynamic studies for Urge syndrome and dysfunctional voiding: a multicenter controlled trial in children.

  The Journal of urology 20081001

• New treatment protocol for primary nocturnal enuresis in children according to ultrasound bladder measurements.

  Saudi medical journal 20081001

• Fixed drug eruption to oxybutynin.

  Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics 20080901

• Intravesical oxybutynin for children with poorly compliant neurogenic bladder: a systematic review.

  The Journal of urology 20080901

• Efficacy and safety of extended-release oxybutynin in combination with tamsulosin for treatment of lower urinary tract symptoms in men: randomized, double-blind, placebo-controlled study.

  Mayo Clinic proceedings 20080901

• Prospective randomized comparison of oxybutynin, functional electrostimulation, and pelvic floor training for treatment of detrusor overactivity in women.

  International urogynecology journal and pelvic floor dysfunction 20080801

• Formulation study of intravesical oxybutynin instillation solution with enhanced retention in bladder.

  Chemical & pharmaceutical bulletin 20080801

• Sustainability of remission of pediatric primary nocturnal enuresis--comparison of remission using Try for Dry vs. non-Try for Dry treatment plans.

  Urologic nursing 20080801

• Semiparametric mixed-effects analysis of PK/PD models using differential equations.

  Journal of pharmacokinetics and pharmacodynamics 20080801

• Therapeutic effects of the putative P2X3/P2X2/3 antagonist A-317491 on cyclophosphamide-induced cystitis in rats.

  Naunyn-Schmiedeberg's archives of pharmacology 20080601

• In vivo characterization of muscarinic receptors in peripheral tissues: evaluation of bladder selectivity of anticholinergic agents to treat overactive bladder.

  Naunyn-Schmiedeberg's archives of pharmacology 20080601

• Estimation of the impact of noncompliance on pharmacokinetics: an analysis of the influence of dosing regimens.

  British journal of clinical pharmacology 20080601

• Transient bilateral blindness and posterior reversible encephalopathy syndrome: a rare complication of enuresis treatment.

  Journal of paediatrics and child health 20080601

• Effective treatment of neurogenic detrusor dysfunction by combined high-dosed antimuscarinics without increased side-effects.

  European urology 20080501

• A prospective, randomized, double-blinded placebo-controlled comparison of extended release oxybutynin versus phenazopyridine for the management of postoperative ureteral stent discomfort.

  Urology 20080501

• Dual use of bladder anticholinergics and cholinesterase inhibitors: long-term functional and cognitive outcomes.

  Journal of the American Geriatrics Society 20080501

• Randomized, placebo-controlled trial of the cognitive effect, safety, and tolerability of oral extended-release oxybutynin in cognitively impaired nursing home residents with urge urinary incontinence.

  Journal of the American Geriatrics Society 20080501

• Persistence, adherence, and switch rates among extended-release and immediate-release overactive bladder medications in a regional managed care plan.

  Journal of managed care pharmacy : JMCP 20080401

• Systematic review: randomized, controlled trials of nonsurgical treatments for urinary incontinence in women.

  Annals of internal medicine 20080318

• Does oxybutynin alter plaques, amyloid beta peptides and behavior in a mouse model of Alzheimer's disease?

  The Journal of urology 20080301

• Oxybutynin effects on Staphylococcus epidermidis biofilm production.

  Southern medical journal 20080301

• Vesicoureteric reflux deterioration in monozygotic twins.

  Indian journal of pediatrics 20080301

• [High performance liquid chromatographic separation of oxybutynin enantiomers using chiral mobile phase additive].

  Se pu = Chinese journal of chromatography 20080301

• Rehabilitation versus drug therapy for urge urinary incontinence: long-term outcomes.

  International urogynecology journal and pelvic floor dysfunction 20080101

• Pharmacologic evaluation of pressor and visceromotor reflex responses to bladder distension.

  Neurourology and urodynamics 20080101

• The effects of anticholinergic drugs on attention span and short-term memory skills in children.

  Neurourology and urodynamics 20080101

• Effects of oxybutynin transdermal system on health-related quality of life and safety in men with overactive bladder and prostate conditions.

  International journal of clinical practice 20080101

• Better management of patients with overactive bladder with antimuscarinics?

  International journal of clinical practice 20080101

• Evolution of transdermal oxybutynin in the treatment of overactive bladder.

  International journal of clinical practice 20080101

• Survey assessment of continuation of and satisfaction with pharmacological treatment for urinary incontinence.

  Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 20080101

• Exercise-induced sweating in healthy subjects as a model to predict a drug's sweat-reducing properties in hyperhydrosis: a prospective, placebo-controlled, double-blind study.

  Acta dermato-venereologica 20080101

• A new method for producing urinary bladder hyperactivity using a non-invasive transient intravesical infusion of acetic acid in conscious rats.

  Journal of pharmacological and toxicological methods 20080101

• Effect of oxybutynin on exercise-induced sweating in healthy individuals.

  The Journal of dermatological treatment 20080101

• Treatment outcome of day-time urinary incontinence in children.

  Scandinavian journal of urology and nephrology 20080101

• [Comparative characteristics of M-cholinolytics in combined treatment of mixed urinary incontinence in women].

  Urologiia (Moscow, Russia : 1999) 20080101

• Polymeric matrix membrane sensors for stability-indicating potentiometric determination of oxybutynin hydrochloride and flavoxate hydrochloride urogenital system drugs.

  Journal of AOAC International 20080101

• Clinical and urodynamic efficacy of oxybutynin and verapamil in the treatment of nocturnal enuresis after formation of orthotopic ileal neobladders. A prospective, randomized, crossover study.

  Scandinavian journal of urology and nephrology 20080101

• The MATRIX study: assessment of health-related quality of life in adults with the use of transdermal oxybutynin.

  Director (Cincinnati, Ohio) 20080101

• The MATRIX study: evaluating the data in older adults.

  Director (Cincinnati, Ohio) 20080101

• The MATRIX study: evaluating the data in older adults.

  Director (Cincinnati, Ohio) 20080101

• Oxybutynin-associated esotropia.

  Journal of AAPOS : the official publication of the American Association for Pediatric Ophthalmology and Strabismus 20071201

• Vardenafil improves urodynamic parameters in men with spinal cord injury: results from a single dose, pilot study.

  The Journal of urology 20071101

• Do holding exercises or antimuscarinics increase maximum voided volume in monosymptomatic nocturnal enuresis? A randomized controlled trial in children.

  The Journal of urology 20071101

• The preparation and human muscarinic receptor profiling of oxybutynin and N-desethyloxybutynin enantiomers.

  Medicinal chemistry (Shariqah (United Arab Emirates)) 20071101

• Comparative in vivo uroselectivity profiles of anticholinergics, tested in a novel anesthetized rabbit model.

  European journal of pharmacology 20071031

• Adsorptive stripping voltammetric behavior and determination of anticholinergic agent oxybutynin chloride on a mercury electrode.

  Journal of colloid and interface science 20071015

• Sublingual oxybutynin reduces postoperative pain related to indwelling bladder catheter after radical retropubic prostatectomy.

  British journal of anaesthesia 20071001

• Postpubertal urodynamic and upper urinary tract changes in children with conservatively treated myelomeningocele.

  The Journal of urology 20071001

• The effect of oxybutynin on structural changes of the obstructed guinea pig bladder.

  The Journal of urology 20071001

• Treatment of nocturnal enuresis in children with attention deficit hyperactivity disorder.

  The Journal of urology 20071001

• The durability of intravesical oxybutynin solutions over time.

  The Journal of urology 20071001

• Office management of pediatric primary nocturnal enuresis: a comparison of physician advised and parent chosen alternative treatment outcomes.

  The Journal of urology 20071001

• Oxybutynin for hyperhidrosis.

  The Netherlands journal of medicine 20071001

• Randomized trial of oxybutynin extended versus immediate release for women aged 65 and older with overactive bladder: lessons learned from conducting a trial.

  Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC 20070901

• Formulation and optimization of porous osmotic pump-based controlled release system of oxybutynin.

  AAPS PharmSciTech 20070901

• Pharmacologic management of overactive bladder.

  Clinical interventions in aging 20070901

• Number of daytime micturitions and volume voided per micturition in the evaluation of efficacy of drugs for overactive bladder: findings from randomized clinical trials.

  European urology 20070801

• Urodynamic evaluation in primary enuresis: an investigative and treatment outcome correlation.

  Journal of tropical pediatrics 20070801

• Patient satisfaction with extended release tolterodine or oxybutynin in overactive bladder.

  Current medical research and opinion 20070801

• Re: Rufus Cartwright and Linda Cardozo. Transdermal oxybutynin: sticking to the facts. Eur urol 2007;51:907-14.

  European urology 20070701

• Analysis of pharmacological effects of drugs used for treatment of urinary disturbance based on anticholinergic and smooth muscle-relaxing effects.

  Biological & pharmaceutical bulletin 20070701

• Comparison of the efficacy, safety, and tolerability of propiverine and oxybutynin for the treatment of overactive bladder syndrome.

  International journal of urology : official journal of the Japanese Urological Association 20070701

• Binding activities by propiverine and its N-oxide metabolites of L-type calcium channel antagonist receptors in the rat bladder and brain.

  Life sciences 20070606

• Transdermal oxybutynin: a review.

  Expert opinion on drug metabolism & toxicology 20070601

• Therapeutic options in childhood nocturnal enuresis.

  Minerva urologica e nefrologica = The Italian journal of urology and nephrology 20070601

• Update on drugs for overactive bladder syndrome.

  Drug and therapeutics bulletin 20070601

• Assessing urinary incontinence in women.

  Nursing times 20070601

• Pharmacokinetics/pharmacodynamics analysis of the relationship between the in vivo micturition pressure and receptor occupancy of (R)-oxybutynin and its metabolite in rats.

  Biological & pharmaceutical bulletin 20070501

• Treatment of overactive bladder: selective use of anticholinergic agents with low drug-drug interaction potential.

  Geriatrics 20070501

• Overactive bladder: recognition requires vigilance for symptoms.

  Cleveland Clinic journal of medicine 20070501

• Rehabilitation vs drug therapy for urge urinary incontinence: short-term outcome.

  International urogynecology journal and pelvic floor dysfunction 20070401

• Transdermal oxybutynin: sticking to the facts.

  European urology 20070401

• Oxybutynin transdermal system improves the quality of life in adults with overactive bladder: a multicentre, community-based, randomized study.

  BJU international 20070401

• The influence of galantamine on reaction time, attention processes, and performance variability in elderly Alzheimer patients.

  Journal of clinical psychopharmacology 20070401

• Treatment of hyperhidrosis with oxybutynin.

  Archives of dermatology 20070401

• Skin permeation enhancement potential of Aloe Vera and a proposed mechanism of action based upon size exclusion and pull effect.

  International journal of pharmaceutics 20070321

• Pharmacokinetics and pharmacodynamics of once-daily controlled-release oxybutynin and immediate-release oxybutynin.

  Journal of clinical pharmacology 20070301

• The effects of external heating on the permeation of oxybutynin through human epidermal membrane.

  Biological & pharmaceutical bulletin 20070301

• [Primary enuresis -- combination therapy with oxybutynin plus desmopressin shows good results].

  Aktuelle Urologie 20070301

• 1,5-Benzodioxepin derivatives as a novel class of muscarinic M3 receptor antagonists.

  Bioorganic & medicinal chemistry letters 20070215

• Comparative evaluation of central muscarinic receptor binding activity by oxybutynin, tolterodine and darifenacin used to treat overactive bladder.

  The Journal of urology 20070201

• Propiverine compared to oxybutynin in neurogenic detrusor overactivity--results of a randomized, double-blind, multicenter clinical study.

  European urology 20070101

• Intravesical atropine compared to oral oxybutynin for neurogenic detrusor overactivity: a double-blind, randomized crossover trial.

  The Journal of urology 20070101

• Stereoselective pharmacokinetics of oxybutynin and N-desethyloxybutynin in vitro and in vivo.

  Xenobiotica; the fate of foreign compounds in biological systems 20070101

• Pharmacological characterization of a new antimuscarinic agent, solifenacin succinate, in comparison with other antimuscarinic agents.

  Biological & pharmaceutical bulletin 20070101

• Oxybutynin for refractory hot flashes in cancer patients.

  Menopause (New York, N.Y.) 20070101

• Beta2-agonists and paresthesias in multiple sclerosis.

  Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology 20070101

• Male overactive bladder: the role of urodynamics and anticholinergics.

  Current urology reports 20070101

• Safety and tolerability of extended-release oxybutynin once daily in urinary incontinence: combined results from two phase 4 controlled clinical trials.

  International urology and nephrology 20070101

• Formulation study of oxybutynin patches.

  Pharmaceutical development and technology 20070101

• [Changes in lower urinary tract function in children with hyperactive urinary bladder treated with combined therapy].

  Urologiia (Moscow, Russia : 1999) 20070101

• A rational combination of intravesical and systemic agents for the treatment of interstitial cystitis.

  Scandinavian journal of urology and nephrology 20070101

• [Oxybutynin-Kentera].

  Journal de pharmacie de Belgique 20070101

• The effectiveness of intravesical oxybutynin, propantheline, and capsaicin in the management of neuropathic bladder following spinal cord injury.

  TheScientificWorldJournal 20070101

• Nocturnal enuresis in children.

  The journal of family health care 20070101

• Retrospective evaluation of outcomes in patients with overactive bladder receiving tolterodine versus oxybutynin.

  American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20061201

• The impact of the overactive bladder syndrome on sexual function: a preliminary report from the Multicenter Assessment of Transdermal Therapy in Overactive Bladder with Oxybutynin trial.

  American journal of obstetrics and gynecology 20061201

• New developments in the treatment of urinary incontinence.

  Minerva urologica e nefrologica = The Italian journal of urology and nephrology 20061201

• New transdermal bioadhesive film containing oxybutynin: In vitro permeation across rabbit ear skin.

  International journal of pharmaceutics 20061115

• The puzzle of overactive bladder: controversies, inconsistencies, and insights.

  International urogynecology journal and pelvic floor dysfunction 20061101

• Oxybutynin in detrusor overactivity.

  The Urologic clinics of North America 20061101

• Transdermal oxybutynin for overactive bladder.

  The Urologic clinics of North America 20061101

• Treatment of the overactive bladder syndrome with muscarinic receptor antagonists: a matter of metabolites?

  Naunyn-Schmiedeberg's archives of pharmacology 20061101

• Comparison of electric stimulation and oxybutynin chloride in management of overactive bladder with special reference to urinary urgency: a randomized placebo-controlled trial.

  Urology 20061101

• Urinary incontinence in women.

  Nursing times 20061101

• [Intravesical treatment of overactive bladder syndrome].

  Der Urologe. Ausg. A 20061001

• Naftopidil monotherapy vs naftopidil and an anticholinergic agent combined therapy for storage symptoms associated with benign prostatic hyperplasia: A prospective randomized controlled study.

  International journal of urology : official journal of the Japanese Urological Association 20061001

• Oxybutynin: dry days for patients with hyperhidrosis.

  The Netherlands journal of medicine 20061001

• Improved efficacy of extended release oxybutynin in children with persistent daytime urinary incontinence converted from regular oxybutynin.

  Urology 20061001

• Effectiveness and tolerability of extended-release oxybutynin vs extended-release tolterodine in women with or without prior anticholinergic treatment for overactive bladder.

  International urogynecology journal and pelvic floor dysfunction 20060901

• Altered neurogenic and mechanical responses to acetylcholine, ATP and substance P in detrusor from rat with outlet obstruction.

  Life sciences 20060822

• Differential effects of the antimuscarinic agents darifenacin and oxybutynin ER on memory in older subjects.

  European urology 20060801

• The role of bladder capacity in antidiuretic and anticholinergic treatment for nocturnal enuresis.

  The Journal of urology 20060801

• A meta-analysis comparing trials of antimuscarinic medications funded by industry or not.

  BJU international 20060801

• Patient-reported outcomes in overactive bladder: importance for determining clinical effectiveness of treatment.

  Urology 20060801

• Oxybutynin therapy for generalized hyperhidrosis.

  Archives of dermatology 20060801

• Prediction of Medicare drug formulary drugs for treatment of overactive bladder.

  The Journal of urology 20060701

• Comparative evaluation of exocrine muscarinic receptor binding characteristics and inhibition of salivation of solifenacin in mice.

  Biological & pharmaceutical bulletin 20060701

• Comparison of the effects of percutaneous and intraduodenal administration of oxybutynin on bladder contraction and salivation in rabbits.

  International journal of urology : official journal of the Japanese Urological Association 20060701

• Comparison of the efficacy, safety, and tolerability of propiverine and oxybutynin for the treatment of overactive bladder syndrome.

  International journal of urology : official journal of the Japanese Urological Association 20060601

• Transdermal oxybutynin in the treatment of overactive bladder.

  Clinical interventions in aging 20060601

• Stoller afferent nerve stimulation in woman with therapy resistant over active bladder; a 1-year follow up.

  International urogynecology journal and pelvic floor dysfunction 20060501

• Microsphere-based protease assays and screening application for lethal factor and factor Xa.

  Cytometry. Part A : the journal of the International Society for Analytical Cytology 20060501

• Frequency of wetting is predictive of response to anticholinergic treatment in children with overactive bladder.

  Urology 20060501

• Biantennary glycans as well as genetic variants of alpha1-acid glycoprotein control the enantioselectivity and binding affinity of oxybutynin.

  Pharmaceutical research 20060501

• Omnibus permutation tests of the overall null hypothesis in datasets with many covariates.

  Journal of biopharmaceutical statistics 20060501

• The overactive bladder: review of current pharmacotherapy in adults. Part 1: pathophysiology and anticholinergic therapy.

  Expert opinion on pharmacotherapy 20060401

• Advantages for transdermal over oral oxybutynin to treat overactive bladder: Muscarinic receptor binding, plasma drug concentration, and salivary secretion.

  The Journal of pharmacology and experimental therapeutics 20060301

• Comparison of efficacy of oxybutynin and tolterodine for prevention of catheter related bladder discomfort: a prospective, randomized, placebo-controlled, double-blind study.

  British journal of anaesthesia 20060301

• A double-blind randomized dose-response study comparing daily doses of 5, 10 and 15 mg controlled-release oxybutynin: balancing efficacy with severity of dry mouth.

  BJU international 20060301

• Using anticholinergics to treat overactive bladder: the issue of treatment tolerability.

  The American journal of medicine 20060301

• The emergence of new drugs for overactive bladder.

  Expert opinion on emerging drugs 20060301

• Hallucinations after hypospadias repair.

  Journal of pediatric surgery 20060301

• Intravesical instillation of human urine after oral administration of trospium, tolterodine and oxybutynin in a rat model of detrusor overactivity.

  BJU international 20060201

• [Intravesical therapy for overactive bladder].

  Der Urologe. Ausg. A 20060201

• Intravesical oxybutynin: practicalities of clinical use.

  Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology 20060201

• Comparison of the effectiveness and side-effects of tolterodine and oxybutynin in children with detrusor instability.

  International journal of urology : official journal of the Japanese Urological Association 20060201

• Characterization of muscarinic receptor binding and inhibition of salivation after oral administration of tolterodine in mice.

  European journal of pharmacology 20060104

• Systemic oxybutynin decreases afferent activity of the pelvic nerve of the rat: new insights into the working mechanism of antimuscarinics.

  Neurourology and urodynamics 20060101

• Anticholinergic drugs for overactive bladder.

  American family physician 20060101

• Minimal clinically important change in urinary incontinence detected by a quality of life assessment tool in overactive bladder syndrome with urge incontinence.

  Neurourology and urodynamics 20060101

• The latest in treatments for incontinence in women.

  Nebraska nurse 20060101

• Transdermal drug delivery treatment for overactive bladder.

  International braz j urol : official journal of the Brazilian Society of Urology 20060101

• An approach to daytime wetting in children.

  Advances in pediatrics 20060101

• Psychotic disorder induced by oxybutynin: Presentation of two cases.

  Clinical drug investigation 20060101

• [Diagnosis and treatment of urinary bladder dysfunctions in patients with nephrotuberculosis].

  Urologiia (Moscow, Russia : 1999) 20060101

• Ocular side-effects of tolterodine and oxybutynin, a single-blind prospective randomized trial.

  British journal of clinical pharmacology 20051201

• Effects of Byakko-ka-ninjin-to on salivary secretion and bladder function in rats.

  Journal of ethnopharmacology 20051114

• Bladder-health diaries: an assessment of 3-day vs 7-day entries.

  BJU international 20051101

• Intravesical therapy for overactive bladder.

  Current urology reports 20051101

• Contemporary treatment options for overactive bladder.

  JAAPA : official journal of the American Academy of Physician Assistants 20051101

• Efficacy and safety of extended release oxybutynin for the treatment of urge incontinence: an analysis of data from 3 flexible dosing studies.

  The Journal of urology 20051001

• Quantification of propiverine by liquid chromatography/electrospray tandem mass spectrometry: application to a bioequivalence study of two formulations in healthy subjects.

  Journal of pharmaceutical and biomedical analysis 20050915

• Comparison of effects of treatment of primary nocturnal enuresis with oxybutynin plus desmopressin, desmopressin alone or imipramine alone: a randomized controlled clinical trial.

  The Journal of urology 20050901

• Efficacy and tolerability of darifenacin, a muscarinic M3 selective receptor antagonist (M3 SRA), compared with oxybutynin in the treatment of patients with overactive bladder.

  World journal of urology 20050901

• Refractory monosymptomatic nocturnal enuresis: a combined stepwise approach in childhood and follow-up into adolescence, with attention to the clinical value of normalizing bladder capacity.

  BJU international 20050901

• Transdermal oxybutynin in the treatment of adults with overactive bladder: combined results of two randomized clinical trials.

  World journal of urology 20050901

• Pharmaceutical development and clinical effectiveness of a novel gel technology for transdermal drug delivery.

  Expert opinion on drug delivery 20050901

• High performance liquid chromatographic determination of oxeladin citrate and oxybutynin hydrochloride and their degradation products.

  Farmaco (Societa chimica italiana : 1989) 20050801

• Effect of the proton pump inhibitor omeprazole on the pharmacokinetics of extended-release formulations of oxybutynin and tolterodine.

  Journal of clinical pharmacology 20050801

• Management of overactive bladder in a difficult-to-treat patient with a transdermal formulation of oxybutynin.

  Urologic nursing 20050801

• Which anticholinergic drug for overactive bladder symptoms in adults.

  The Cochrane database of systematic reviews 20050720

• Comparison of darifenacin and oxybutynin in patients with overactive bladder: assessment of ambulatory urodynamics and impact on salivary flow.

  European urology 20050701

• Assessment and management of urinary incontinence.

  The Nurse practitioner 20050701

• Persistence with overactive bladder pharmacotherapy in a Medicaid population.

  The American journal of managed care 20050701

• Medical costs after initiation of drug treatment for overactive bladder: effects of selection bias on cost estimates.

  The American journal of managed care 20050701

• Economic impact of extended-release tolterodine versus immediate- and extended-release oxybutynin among commercially insured persons with overactive bladder.

  The American journal of managed care 20050701

• Treatment of overactive bladder: a model comparing extended-release formulations of tolterodine and oxybutynin.

  The American journal of managed care 20050701

• The effect of oxybutynin treatment on cognition in children with diurnal incontinence.

  The Journal of urology 20050601

• Extended-release formulations of oxybutynin and tolterodine exhibit similar central nervous system tolerability profiles: a subanalysis of data from the OPERA trial.

  American journal of obstetrics and gynecology 20050601

• Muscarinic receptor binding, plasma concentration and inhibition of salivation after oral administration of a novel antimuscarinic agent, solifenacin succinate in mice.

  British journal of pharmacology 20050501

• Ocular side-effects of tolterodine and oxybutynin, a single-blind prospective randomized trial.

  British journal of clinical pharmacology 20050501

• Estimation of dosing strategies aiming at maximizing utility or responder probability, using oxybutynin as an example drug.

  European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 20050501

• Effects of behavioral and drug therapy on nocturia in older incontinent women.

  Journal of the American Geriatrics Society 20050501

• Trospium chloride for the treatment of overactive bladder with urge incontinence.

  Clinical therapeutics 20050501

• Design, synthesis and activity of novel derivatives of oxybutynin and tolterodine.

  Bioorganic & medicinal chemistry letters 20050415

• In vivo demonstration of muscarinic receptor binding activity of N-desethyl-oxybutynin, active metabolite of oxybutynin.

  Life sciences 20050408

• Carbamazepine toxicity following Oxybutynin and Dantrolene administration: a case report.

  Spinal cord 20050401

• Long-term prospective randomized study comparing two different regimens of oxybutynin as a treatment for detrusor overactivity.

  European journal of obstetrics, gynecology, and reproductive biology 20050401

• Influence of estradiol pretreatment on antimuscarinic action of oxybutynin in rat detrusor muscle.

  Urology 20050401

• Influence of micro-environmental pH on the gel layer behavior and release of a basic drug from various hydrophilic matrices.

  Journal of controlled release : official journal of the Controlled Release Society 20050321

• [Development of an intravesial oxybutynin chloride solution: from formulation to quality control].

  Annales pharmaceutiques francaises 20050301

• Effects on sleep of anticholinergics used for overactive bladder treatment in healthy volunteers aged > or = 50 years.

  BJU international 20050201

• Antimuscarinic agents exhibit local inhibitory effects on muscarinic receptors in bladder-afferent pathways.

  Urology 20050201

• Should we switch over to tolterodine in every child with non-neurogenic daytime urinary incontinence in whom oxybutynin failed?

  Urology 20050201

• Overactive bladder: evaluation and management in primary care.

  Cleveland Clinic journal of medicine 20050201

• [Therapy of bladder weakness].

  Deutsche medizinische Wochenschrift (1946) 20050121

• Efficacy and safety of oxybutynin in children with detrusor hyperreflexia secondary to neurogenic bladder dysfunction.

  The Journal of urology 20050101

• [Use of oral anticholinergic therapy in children under 1 years of age with high risk bladder].

  Cirugia pediatrica : organo oficial de la Sociedad Espanola de Cirugia Pediatrica 20050101

• Propantheline and in vitro reactivity of urinary bladder smooth muscle in guinea pigs.

  Bratislavske lekarske listy 20050101

• Persistence and adherence of medications for chronic overactive bladder/urinary incontinence in the california medicaid program.

  Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 20050101

• [Neurological aspect of the hyperactive urinary bladder syndrome].

  Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova 20050101

• A peripheric neuromodulation technique for curing detrusor overactivity: Stoller afferent neurostimulation.

  Scandinavian journal of urology and nephrology 20050101

• Comparison of dry mouth in women treated with extended-release formulations of oxybutynin or tolterodine for overactive bladder.

  International urology and nephrology 20050101

• [Transdermal system].

  Krankenpflege Journal 20050101

• Urodynamic effects of oxybutynin and tolterodine in conscious and anesthetized rats under different cystometrographic conditions.

  BMC pharmacology 20050101

• Pharmacological management of overactive bladder : a systematic and critical review of published economic evaluations.

  PharmacoEconomics 20050101

• [In vitro and in vivo biopharmaceutical evaluation of lorazepam commercial tablets].

  La Clinica terapeutica 20050101

• [Cutaneous administration rather than swallowing].

  Krankenpflege Journal 20050101

• Nocturnal enuresis in children. A four-year experience in outpatient clinics of pediatric urology.

  Folia medica 20050101

• Transdermal oxybutynin (oxytrol) for urinary incontinence.

  American family physician 20041215

• Comparison of the efficacy of tolterodine and oxybutynin in different urodynamic severity grades of idiopathic detrusor overactivity.

  European urology 20041201

• Update on nocturia: the best of rest is sleep.

  Urology 20041201

• Rapid and selective UV spectrophotometric and RP-HPLC methods for dissolution studies of oxybutynin immediate-release and controlled-release formulations.

  Journal of pharmaceutical and biomedical analysis 20041115

• Oxybutynin for treatment of urge urinary incontinence and overactive bladder: an updated review.

  Expert opinion on pharmacotherapy 20041101

• Demonstration of bladder selective muscarinic receptor binding by intravesical oxybutynin to treat overactive bladder.

  The Journal of urology 20041101

• Health-related quality of life of Japanese patients with overactive bladder treated with extended-release tolterodine or immediate-release oxybutynin: a randomized, placebo-controlled trial.

  World journal of urology 20041001

• Effect of controlled-release delivery on the pharmacokinetics of oxybutynin at different dosages: severity-dependent treatment of the overactive bladder.

  BJU international 20041001

• Elevating our therapeutic expectations in overactive bladder.

  Journal of the American Academy of Nurse Practitioners 20041001

• Double-blind randomized controlled trial assessing the safety and efficacy of intravesical agents for ureteral stent symptoms after extracorporeal shockwave lithotripsy.

  Journal of endourology 20041001

• Bilateral spontaneous perinephric urinomas: case report and review of the literature.

  Urology 20040901

• Recent changes to FDA-approved labeling.

  American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20040901

• Urodynamic effects and safety of modified intravesical oxybutynin chloride in patients with neurogenic detrusor overactivity: 3 years experience.

  International journal of urology : official journal of the Japanese Urological Association 20040801

• Nocturnal enuresis: medical management.

  The Urologic clinics of North America 20040801

• Effects of ryanoids on spontaneous and depolarization-evoked calcium release events in frog muscle.

  Biophysical journal 20040701

• A randomized, double-blind, parallel-group comparison of controlled- and immediate-release oxybutynin chloride in urge urinary incontinence.

  Clinical therapeutics 20040701

• A population pharmacokinetic model with time-dependent covariates measured with errors.

  Biometrics 20040601

• In vitro and in vivo tissue selectivity profile of solifenacin succinate (YM905) for urinary bladder over salivary gland in rats.

  European journal of pharmacology 20040525

• [Effect of 4-ethylamino-2-butynyl(2-cyclohexyl-2-phenyl) glycolate, metabolite of oxybutynin, on intra-artery administered acetylcholine-induced urinary bladder contraction in anesthetized dogs].

  Nihon yakurigaku zasshi. Folia pharmacologica Japonica 20040501

• Use of the short form of King's Health Questionnaire to measure quality of life in patients with an overactive bladder.

  BJU international 20040501

• Behavioral and drug therapy for urinary incontinence.

  Urology 20040301

• Overactive bladder. Strategies for better recognition and management.

  Advance for nurse practitioners 20040301

• Canadian economic comparison of extended-release oxybutynin and immediate-release tolterodine in the treatment of overactive bladder.

  Clinical therapeutics 20040301

• Can higher doses of oxybutynin improve efficacy in neurogenic bladder?

  The Journal of urology 20040201

• Inhibition of hyperreflexia by vaginally administered oxybutynin: a novel rabbit model.

  The Journal of urology 20040201

• Drug approval highlights for 2003.

  The Nurse practitioner 20040201

• Effects of 4-ethylamino-2-butynyl(2-cyclohexyl-2-phenyl)glycolate hydrochloride, a metabolite of oxybutynin, on bladder specimens and rhythmic bladder contraction in rats in comparison with oxybutynin.

  Journal of pharmacological sciences 20040201

• Comparison of in vitro selectivity profiles of solifenacin succinate (YM905) and current antimuscarinic drugs in bladder and salivary glands: a Ca2+ mobilization study in monkey cells.

  Life sciences 20040102

• Acupuncture reflexotherapy in the treatment of sensory urgency that persists after transurethral resection of the prostate: a preliminary report.

  Neurourology and urodynamics 20040101

• Preliminary evaluation of a new controlled-release oxybutynin in urinary incontinence.

  Current medical research and opinion 20040101

• Oxybutynin extended-release: a review of its use in the management of overactive bladder.

  Drugs 20040101

• Comparative tolerability of drug treatment for nocturnal enuresis in children.

  Drug safety 20040101

• Detrusor overactivity in spina bifida: how long does it need to be treated?

  Neurourology and urodynamics 20040101

• Efficacy and safety of tolterodine in people with neurogenic detrusor overactivity.

  The journal of spinal cord medicine 20040101

• Trospium chloride in the management of overactive bladder.

  Drugs 20040101

• A comparison of extended-release oxybutynin and tolterodine for treatment of overactive bladder in women.

  International urogynecology journal and pelvic floor dysfunction 20040101

• Cost-effectiveness analysis of extended-release formulations of oxybutynin and tolterodine for the management of urge incontinence.

  PharmacoEconomics 20040101

• Effect of antacid on the pharmacokinetics of extended-release formulations of tolterodine and oxybutynin.

  Clinical pharmacokinetics 20040101

• Improved precision and accuracy for high-performance liquid chromatography/Fourier transform ion cyclotron resonance mass spectrometric exact mass measurement of small molecules from the simultaneous and controlled introduction of internal calibrants via a second electrospray nebuliser.

  Rapid communications in mass spectrometry : RCM 20040101

• Muscarinic receptors: what we know.

  Current urology reports 20031201

• Overactive bladder: improving the efficacy of anticholinergics by dose escalation.

  Current urology reports 20031201

• Transdermal oxybutynin: a new treatment for overactive bladder.

  Expert opinion on pharmacotherapy 20031201

• Clinical efficacy and tolerability of extended-release tolterodine and immediate-release oxybutynin in Japanese and Korean patients with an overactive bladder: a randomized, placebo-controlled trial.

  BJU international 20031101

• Urinary incontinence. Solving a secret problem.

  Nursing 20031101

• Update on overactive bladder: pharmacologic approaches on the horizon.

  Current urology reports 20031001

• [In which patients is the oxybutynin-desmopressin combination therapy indicated?].

  Cirugia pediatrica : organo oficial de la Sociedad Espanola de Cirugia Pediatrica 20031001

• Design of a silicone reservoir intravaginal ring for the delivery of oxybutynin.

  Journal of controlled release : official journal of the Controlled Release Society 20030904

• RE: Therapeutic efficacy of extended release oxybutynin chloride, and immediate release and long acting tolterodine tartrate in children with diurnal urinary incontinence.

  The Journal of urology 20030901

• Urodynamic verification of an overactive bladder is not a prerequisite for antimuscarinic treatment response.

  BJU international 20030901

• The action of oxybutynin on haemodynamics and metabolism in the perfused rat liver.

  Pharmacology & toxicology 20030901

• Comparative efficacy and safety of transdermal oxybutynin and oral tolterodine versus placebo in previously treated patients with urge and mixed urinary incontinence.

  Urology 20030801

• Oxytrol approved for overactive bladder.

  The Nurse practitioner 20030801

• Skin patch approved for treatment of overactive bladder.

  Mayo Clinic women's healthsource 20030801

• Oxybutynin for diagnosis of infravesical obstruction in boys with urinary incontinence.

  Urology 20030701

• Urodynamics in a rat neurogenic bladder model with a unilateral electrolytic lesion of the basal forebrain.

  BJU international 20030601

• Effectiveness of vaginally administered oxybutynin on rabbit bladder function.

  Urology 20030601

• Effectiveness of iontophoresis with alternating current (AC) in the treatment of patients with palmoplantar hyperhidrosis.

  The Journal of dermatology 20030601

• Advances in medical management of overactive bladder.

  Mayo Clinic proceedings 20030601

• Prospective, randomized, double-blind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overactive bladder: results of the OPERA trial.

  Mayo Clinic proceedings 20030601

• Pharmacokinetics, metabolism, and saliva output during transdermal and extended-release oral oxybutynin administration in healthy subjects.

  Mayo Clinic proceedings 20030601

• Oxybutynin transdermal (Oxytrol) for overactive bladder.

  The Medical letter on drugs and therapeutics 20030512

• Intravesical oxybutynin: a local anesthetic effect on bladder C afferents.

  The Journal of urology 20030501

• [The medical treatment of overactive bladder].

  Neuro-Chirurgie 20030501

• Controlled, double-blind, multicentre clinical trial to investigate long-term tolerability and efficacy of trospium chloride in patients with detrusor instability.

  World journal of urology 20030501

• [Urinary incontinence--treatment].

  Deutsche medizinische Wochenschrift (1946) 20030404

• Which stop test is best? Measuring detrusor contractility in older females.

  The Journal of urology 20030301

• The use of tolterodine in children after oxybutynin failure.

  BJU international 20030301

• A thirteen-year-old girl with anemia.

  Pediatric annals 20030301

• Sensitive determination of oxybutynin and desethyloxybutynin in dog plasma by LC-ESI/MS/MS.

  Journal of pharmaceutical and biomedical analysis 20030226

• Therapeutic efficacy of extended release oxybutynin chloride, and immediate release and long acting tolterodine tartrate in children with diurnal urinary incontinence.

  The Journal of urology 20030101

• Pharmacokinetics and metabolism of transdermal oxybutynin: in vitro and in vivo performance of a novel delivery system.

  Pharmaceutical research 20030101

• Effect of controlled-release oxybutynin on neurogenic bladder function in spinal cord injury.

  The journal of spinal cord medicine 20030101

• [Spasmex treatment of patients with hyperactive urinary bladder].

  Urologiia (Moscow, Russia : 1999) 20030101

• Transdermal oxybutynin: for overactive bladder.

  Drugs & aging 20030101

• Transdermal oxybutynin. A viewpoint by Michael Chancellor.

  Drugs & aging 20030101

• Transdermal oxybutynin. A viewpoint by Adrian Wagg.

  Drugs & aging 20030101

• Acupressure versus oxybutinin in the treatment of enuresis.

  The Journal of international medical research 20030101

• Methodologic shortcomings inherent in a post-hoc analysis.

  Current urology reports 20021201

• Advances in drug delivery: improved bioavailability and drug effect.

  Current urology reports 20021201

• Value of increase in bladder capacity in treatment of refractory monosymptomatic nocturnal enuresis in children.

  Urology 20021201

• Significance of low compliance bladder in cauda equina injury.

  Spinal cord 20021201

• Different responses to drugs against overactive bladder in detrusor muscle of pig, guinea pig and mouse.

  European journal of pharmacology 20021101

• Conservative management in neurogenic bladder dysfunction.

  Current opinion in urology 20021101

• New perspectives on the overactive bladder: pharmacokinetics and bioavailability.

  Urology 20021101

• Future studies of overactive bladder: the need for standardization.

  Urology 20021101

• Treatment of overactive bladder: the Antimuscarinic Clinical Effectiveness Trial.

  Current urology reports 20021001

• Pharmacologic treatment for detrusor overactivity.

  Current urology reports 20021001

• The newer antimuscarinic drugs: bladder control with less dry mouth.

  Cleveland Clinic journal of medicine 20021001

• (S)-oxybutynin (Sepracor).

  Current opinion in investigational drugs (London, England : 2000) 20021001

• A randomized controlled trial of tolterodine and oxybutynin on tolerability and clinical efficacy for treating Chinese women with an overactive bladder.

  BJU international 20020901

• M(3) receptor antagonism by the novel antimuscarinic agent solifenacin in the urinary bladder and salivary gland.

  Naunyn-Schmiedeberg's archives of pharmacology 20020801

• Efficacy and safety of transdermal oxybutynin in patients with urge and mixed urinary incontinence.

  The Journal of urology 20020801

• Can oxybutynin cause peripheral neuropathy?

  The Journal of urology 20020801

• Current pharmacotherapeutic strategies for overactive bladder.

  Expert opinion on pharmacotherapy 20020701

• The overactive bladder: a nursing perspective.

  The American journal of nursing 20020601

• Assessment and conservative management of the neuropathic bladder.

  Seminars in pediatric surgery 20020501

• The management of urinary incontinence in the exstrophy complex, posterior urethral valves, and infrasphincteric ureters.

  Seminars in pediatric surgery 20020501

• Urodynamic changes associated with behavioral and drug treatment of urge incontinence in older women.

  Journal of the American Geriatrics Society 20020501

• Advances in anticholinergic therapy delivery systems.

  Geriatrics 20020501

• Tolterodine: as effective but better tolerated than oxybutynin in Asian patients with symptoms of overactive bladder.

  International journal of urology : official journal of the Japanese Urological Association 20020501

• Achieving bladder control. Treatment in the primary care setting.

  Advance for nurse practitioners 20020501

• Oxybutynin chloride: alterations in drug delivery and improved therapeutic index.

  Expert opinion on pharmacotherapy 20020401

• Vesicoureteral reflux and bladder management in spinal cord injury patients.

  Spinal cord 20020301

• Pharmacotherapy of the overactive bladder and advances in drug delivery.

  Clinical obstetrics and gynecology 20020301

• Preliminary study of the safety and efficacy of extended-release oxybutynin in children.

  Urology 20020301

• Plasma protein binding study of oxybutynin by high-performance frontal analysis.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20020225

• Enuresis.

  Southern medical journal 20020201

• Medication update.

  Southern medical journal 20020201

• Pharmacokinetics, efficacy, and safety of intravesical formulation of oxybutynin in patients with detrusor overactivity.

  Scandinavian journal of urology and nephrology 20020201

• Determination of an optimal dosage regimen using a Bayesian decision analysis of efficacy and adverse effect data.

  Journal of pharmacokinetics and pharmacodynamics 20020201

• Actions of the new antimuscarinic compound Lu 25-109 on isolated human and pig detrusor.

  Neurourology and urodynamics 20020101

• Treatment can lead to a long dry spell.

  Business and health 20020101

• Once-daily, extended-release formulations of antimuscarinic agents in the treatment of overactive bladder: a review.

  European urology 20020101

• Tolterodine: selectivity for the urinary bladder over the eye (as measured by visual accommodation) in healthy volunteers.

  Drugs in R&D 20020101

• Oxybutynin intravesical--situs. I-oxy.

  Drugs in R&D 20020101

• S-oxybutynin.

  Drugs in R&D 20020101

• New treatment options for overactive bladder and incontinence.

  Director (Cincinnati, Ohio) 20020101

• Treatment of overactive bladder with once-daily extended-release tolterodine or oxybutynin: the antimuscarinic clinical effectiveness trial (ACET).

  Current medical research and opinion 20020101

• A benefit-risk assessment of extended-release oxybutynin.

  Drug safety 20020101

• Long-term safety of extended-release oxybutynin chloride in a community-dwelling population of participants with overactive bladder: a one-year study.

  International urology and nephrology 20020101

• [Therapeutic effects of intrarectal administration of oxybutynin].

  Wiadomosci lekarskie (Warsaw, Poland : 1960) 20020101

• Intravesical oxybutynin: mode of action assessed by passive diffusion and electromotive administration with pharmacokinetics of oxybutynin and N-desethyl oxybutynin.

  The Journal of urology 20011201

• Intravesical treatment of bladder dysfunction.

  The Journal of urology 20011201

• Oxybutynin, desmopressin and enuresis.

  The Journal of urology 20011201

• Is tolterodine (Detrol) or oxybutynin (Ditropan) the best for treatment of urge urinary incontinence?

  The Journal of family practice 20011201

• Cost-Effectiveness of tolterodine for patients with urge incontinence who discontinue initial therapy with oxybutynin: a Canadian perspective.

  Clinical therapeutics 20011201

• Evidence based management of nocturnal enuresis.

  BMJ (Clinical research ed.) 20011117

• Medical treatment of overactive bladder.

  Mayo Clinic proceedings 20011101

• Oxybutynin and the overactive bladder.

  World journal of urology 20011101

• Is attempting suicide an adverse effect of oxybutynin in a child with enuresis nocturna?

  Pediatric emergency care 20011001

• POEMS (patient-oriented evidence that matters) spark discussion.

  The Journal of family practice 20011001

• Treatment of childhood nocturnal enuresis: an examination of clinically relevant principles.

  BJU international 20011001

• Effect of OROS controlled-release delivery on the pharmacokinetics and pharmacodynamics of oxybutynin chloride.

  British journal of clinical pharmacology 20011001

• Tolterodine: a clinical review.

  Journal of women's health & gender-based medicine 20011001

• Combination therapy for nocturnal enuresis.

  Scandinavian journal of urology and nephrology 20011001

• Effects of antimuscarinic drugs on both urinary frequency and cognitive impairment in conscious, nonrestrained rats.

  Japanese journal of pharmacology 20010901

• Effects of AH-9700, (+)-pentazocine, DTG and oxybutynin on micturition in anesthetized rats with acetone-induced cystitis.

  Life sciences 20010824

• Nocturnal enuresis.

  The Western journal of medicine 20010801

• Costs and resources associated with the treatment of overactive bladder using retrospective medical care claims data.

  Managed care interface 20010801

• Combined pharmacotherapy for nocturnal enuresis.

  Pediatric nephrology (Berlin, Germany) 20010801

• Comparison of the inhibitory effects of cromakalim and pinacidil (potassium channel openers) with those of oxybutynin on stimulated guinea pig and rabbit detrusor muscle strips.

  Archives of gynecology and obstetrics 20010801

• A short-term, multicenter, randomized double-blind dose titration study of the efficacy and anticholinergic side effects of transdermal compared to immediate release oral oxybutynin treatment of patients with urge urinary incontinence.

  The Journal of urology 20010701

• A crossover randomized trial of transcutaneous electrical nerve stimulation and oxybutynin in patients with detrusor instability.

  The Journal of urology 20010701

• Tolterodine versus oxybutynin in the treatment of urge urinary incontinence: a meta-analysis.

  American journal of obstetrics and gynecology 20010701

• Is extended-release oxybutynin (Ditropan XL) or tolterodine (Detrol) more effective in the treatment of an overactive bladder?

  The Journal of family practice 20010701

• Pharmacokinetics of the R- and S-enantiomers of oxybutynin and N-desethyloxybutynin following oral and transdermal administration of the racemate in healthy volunteers.

  Pharmaceutical research 20010701

• Clarification--Drug risk in patients with glaucoma.

  The Medical letter on drugs and therapeutics 20010611

• A semiparametric deconvolution model to establish in vivo-in vitro correlation applied to OROS oxybutynin.

  Journal of pharmaceutical sciences 20010601

• Effects of tolterodine, trospium chloride, and oxybutynin on the central nervous system.

  Journal of clinical pharmacology 20010601

• Intravesical oxybutynin for treating incontinence resulting from an overactive detrusor.

  BJU international 20010601

• Tolterodine: superior tolerability than and comparable efficacy to oxybutynin in individuals 50 years old or older with overactive bladder: a randomized controlled trial.

  The Journal of urology 20010501

• Side-effects of oral or intravesical oxybutynin chloride in children with spina bifida.

  BJU international 20010501

• Muscarinic receptor binding characteristics in rat tissues after oral administration of oxybutynin and propiverine.

  Biological & pharmaceutical bulletin 20010501

• A comparison of the effects on saliva output of oxybutynin chloride and tolterodine tartrate.

  Clinical therapeutics 20010501

• Clinical experiences with tolterodine.

  Life sciences 20010427

• Detrol LA and Diropan XL for overactive bladder.

  The Medical letter on drugs and therapeutics 20010402

• Functional characterization of rat submaxillary gland muscarinic receptors using microphysiometry.

  British journal of pharmacology 20010401

• Oxybutynin does not affect cyclosporin blood levels.

  Therapeutic drug monitoring 20010401

• Prospective randomized controlled trial of extended-release oxybutynin chloride and tolterodine tartrate in the treatment of overactive bladder: results of the OBJECT Study.

  Mayo Clinic proceedings 20010401

• Preformulation studies on the S-isomer of oxybutynin hydrochloride, an Improved Chemical Entity (ICE).

  Drug development and industrial pharmacy 20010401

• Overactive bladder: optimizing quality of care.

  The American journal of managed care 20010301

• Intravesical electromotive administration of oxybutynin in patients with detrusor hyperreflexia unresponsive to standard anticholinergic regimens.

  The Journal of urology 20010201

• Association between oxybutynin and neuropsychiatric adverse effects not confirmed in daily practice.

  Journal of the American Geriatrics Society 20010201

• Lack of effect of food on the pharmacokinetics of an extended-release oxybutynin formulation.

  Journal of clinical pharmacology 20010201

• Pharmacological actions of AH-9700 on micturition reflex in anesthetized rats.

  European journal of pharmacology 20010126

• [Results of a therapeutic strategy against monosymptomatic nocturnal enuresis].

  Anales espanoles de pediatria 20010101

• Psychological improvements associated with behavioral and drug treatment of urge incontinence in older women.

  The journals of gerontology. Series B, Psychological sciences and social sciences 20010101

• Enuresis.

  Advances in pediatrics 20010101

• Intravesical oxybutynin affects bladder permeability.

  International urology and nephrology 20010101

• [Combined treatment of patients with detrusor instability].

  Urologiia (Moscow, Russia : 1999) 20010101

• Influence of pump compliance (peristaltic vs. infusion) on urodynamic measurement during cystometry in conscious rats.

  Journal of pharmacological and toxicological methods 20010101

• Possible site of action of TAK-637, a tachykinin NK(1) receptor antagonist, on the micturition reflex in guinea pigs.

  European journal of pharmacology 20000804

• Propiverine-induced Parkinsonism: a case report and a pharmacokinetic/pharmacodynamic study in mice.

  Pharmaceutical research 20000501

• Oxybutynin chloride inhibits proliferation and suppresses gene expression in bladder smooth muscle cells.

  The Journal of urology 19990901

• Identification of medications that cause cognitive impairment in older people: the case of oxybutynin chloride.

  Journal of the American Geriatrics Society 19980101

• Oxybutynin and intranasal desmopressin for clozapine-induced urinary incontinence.

  The Journal of clinical psychiatry 19970901

• Bladder dysfunction associated with clozapine therapy.

  The Journal of clinical psychiatry 19960101

• General pharmacology of the new antimuscarinic compound vamicamide.

  Arzneimittel-Forschung 19951201

• Treatment-emergent incontinence with lithium.

  The Journal of clinical psychiatry 19851001

• [Effects of oxybutynin on the cardiovascular system in dogs].

  Nihon yakurigaku zasshi. Folia pharmacologica Japonica 19841001